Lercanidipin Accord (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L-type calcium channels in the smooth muscle of arterial walls. This inhibition reduces calcium entry, preventing muscle contraction, leading to vasodilation, decreased peripheral resistance, and a subsequent reduction in systemic blood pressure.

The appropriate dose of Lercanidipin Accord is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine is a long‑acting dihydropyridine calcium channel blocker, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. Compared with beta‑blockers or ACE inhibitors, it primarily induces vasodilation without affecting heart rate or renin‑angiotensin activity, making it a useful option for patients who need vascular relaxation.

Lercanidipin Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lercanidipin Accord is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water and do not crush or chew it unless specifically instructed.

Serious adverse events, although rare, can include severe hypotension, myocardial infarction, hepatic injury, allergic reactions, and arrhythmias. Patients should seek immediate medical attention if they experience symptoms such as fainting, chest pain, jaundice, rash, or irregular heartbeat.

Lercanidipin Accord is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, and in those with severe aortic stenosis or unstable angina. Caution is also advised for individuals with significant liver impairment or who are taking interacting medications.